scholarly journals Nutritional status disorders and methods of their correction in patients with advanced pancreatic cancer

2022 ◽  
pp. 66-74
Author(s):  
M. A. Kiryukova ◽  
E. A. Dubtsova ◽  
L. V. Vinokurova ◽  
M. V. Malykh ◽  
D. S. Bordin
Keyword(s):  
Pancreatic Cancer ◽  
Nutritional Status ◽  
Cancer Treatment ◽  
Advanced Pancreatic Cancer ◽  
Disease Outcomes

Despite of achieved progress in advanced pancreatic cancer treatment, the disease outcomes remain far from satisfying. The peculiarity of malnutrition treatment in these patients is the result of its causes complexity and progressively growing manifestations extent. The review represents mechanisms of malnutrition and approaches to their treatment.

scholarly journals Advanced pancreatic cancer: The standard of care and new opportunities

2018 ◽  
Author(s):  
Amrallah A. Mohammad
Keyword(s):  
Pancreatic Cancer ◽  
Mortality Rate ◽  
Cancer Treatment ◽  
Molecular Analysis ◽  
Therapeutic Approach ◽  
Locally Advanced ◽  
Advanced Pancreatic Cancer ◽  
Standard Of Care

Presentation of pancreatic cancer is localized, locally advanced or metastatic. With the later represented the main bulk (more than 80%). Despite the significant innovation in molecular analysis and therapeutic approach in many types of cancer in the last two decades, still the outcome of advanced pancreatic cancer is disappointing and the mortality rate approximately unchanged. In this mandated review we intended to highlight the standard of care and emerging agents for advanced pancreatic cancer treatment.

Survival outcomes of advanced pancreatic cancer in an integrative treatment setting: The Cancer Treatment Centers of America experience

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 15188-15188
Author(s):  
C. G. Lis ◽  
R. D. Levin ◽  
R. Neelam ◽  
P. G. Vashi ◽  
C. A. Lammersfeld ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Treatment ◽  
Median Survival ◽  
Advanced Pancreatic Cancer ◽  
Treatment Protocol ◽  
Phase Iii ◽  
Definitive Treatment ◽  
Comprehensive Cancer Center ◽  
Rank Test ◽  
Survival Outcomes

15188 Background: In this study, we report the survival outcomes of patients with advanced pancreatic cancer who underwent intra- arterial mitomycin/cisplatin therapy at Cancer Treatment Centers of America (CTCA), a community hospital comprehensive cancer center combining conventional and integrative medical therapies. Methods: At our center, all patients undergo a comprehensive program of nutritional, spiritual, physical, naturopathic, and emotional support while receiving an aggressive conventional treatment protocol. Using data collected by the cancer registry, we identified 114 consecutively treated newly diagnosed cases of invasive pancreatic cancer who underwent definitive treatment between Jan 01 and Dec 05. Results: 26 patients were stage III and 88 were stage IV. The median age was 58 years (range 31 to 81 years). 55 patients were selected for intra-arterial therapy with mitomycin/cisplatin. These patients had a PS of 2 or better and either had no metastatic lesions or a single localized liver metastasis. 16 patients in this cohort received radiotherapy. The 59 other patients underwent a variety of therapies. Intra-arterially treated patients had a median survival of 369 days and a 2-year cumulative survival of 19%. Patients not treated with intra-arterial therapy had a median survival of 249 days and a 2-year survival of 11%. Univariate survival analysis found that patients undergoing intra-arterial therapy had significantly better survival outcomes compared to patients undergoing different therapies (Log rank test P = 0.04). The table compares the survival outcomes of recent phase III investigations on first line therapies for pancreatic cancer with those at CTCA. Conclusion: Currently, the published clinical trial data in advanced pancreatic indicates a one-year survival ranging from less than 10% to 28%. Consequently, the survival outcomes of patients undergoing therapy at our center warrant further investigation. [Table: see text] No significant financial relationships to disclose.

scholarly journals Nutritional status of patients with locally advanced pancreatic cancer: a pilot study

2010 ◽  
Vol 19 (11) ◽  
pp. 1729-1734 ◽  
Author(s):  
Leah M. Ferrucci ◽  
Diana Bell ◽  
Jennifer Thornton ◽  
Glenda Black ◽  
Ruth McCorkle ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Pilot Study ◽  
Nutritional Status ◽  
Locally Advanced ◽  
Advanced Pancreatic Cancer ◽  
Locally Advanced Pancreatic Cancer

MON-PP086: Severely Impaired Nutritional Status in Patients with Locally Advanced Pancreatic Cancer

2015 ◽  
Vol 34 ◽  
pp. S159-S160
Author(s):  
J. Witvliet ◽  
C. Lochtenberg-Potjes ◽  
H. Scheffer ◽  
G. Kazemier ◽  
N. Wierdsma ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Nutritional Status ◽  
Locally Advanced ◽  
Advanced Pancreatic Cancer ◽  
Locally Advanced Pancreatic Cancer

scholarly journals Assessment of Nutritional Status, Digestion and Absorption, and Quality of Life in Patients with Locally Advanced Pancreatic Cancer

2017 ◽  
Vol 2017 ◽  
pp. 1-7 ◽  
Author(s):  
J. E. Witvliet-van Nierop ◽  
C. M. Lochtenberg-Potjes ◽  
N. J. Wierdsma ◽  
H. J. Scheffer ◽  
G. Kazemier ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Pancreatic Cancer ◽  
Nutritional Status ◽  
Handgrip Strength ◽  
Locally Advanced ◽  
Advanced Pancreatic Cancer ◽  
Serum Vitamin ◽  
Fat Free Mass ◽  
Locally Advanced Pancreatic Cancer

Background and Aim.To provide a comprehensive quantitative assessment of nutritional status, digestion and absorption, and quality of life (QoL) in patients with locally advanced pancreatic cancer (LAPC).Methods.Sixteen patients with LAPC were prospectively assessed for weight loss (WL), body mass index (BMI), fat-free mass index (FFMI), handgrip strength (HGS), dietary macronutrient intake, serum vitamin levels, resting and total energy expenditure (REE and TEE, indirect calorimetry), intestinal absorption capacity and fecal losses (bomb calorimetry), exocrine pancreatic function (fecal elastase-1 (FE1)), and gastrointestinal quality of life (GIQLI).Results.Two patients had a low BMI, 10 patients had WL > 10%/6 months, 8 patients had a FFMI < P10, and 8 patients had a HGS < P10. Measured REE was 33% higher (P=0.002) than predicted REE. TEE was significantly higher than daily energy intake (P=0.047). Malabsorption (<85%) of energy, fat, protein, and carbohydrates was observed in, respectively, 9, 8, 12, and 10 patients. FE1 levels were low (<200 μg/g) in 13 patients. Total QoL scored 71% (ample satisfactory).Conclusion.Patients with LAPC have a severely impaired nutritional status, most likely as a result of an increased REE and malabsorption due to exocrine pancreatic insufficiency. The trial is registered with PANFIRE clinicaltrials.govNCT01939665.

Sign in / Sign up

Export Citation Format

Share Document